Lidoderm Patch Application to Chest After CPR
Do not apply Lidoderm patches to the chest after CPR until at least 4 hours have passed if any local anesthetic was used during resuscitation, and only apply to intact skin—never to broken, traumatized, or abraded skin that may result from chest compressions.
Key Safety Considerations After CPR
Skin Integrity Assessment
The chest wall after CPR frequently has compromised skin integrity from vigorous compressions. Lidoderm patches are contraindicated on non-intact skin 1. Before any application:
- Inspect for bruising, abrasions, or skin breakdown
- Assess for rib fractures (common after CPR) which may indicate underlying tissue trauma
- Wait until skin has fully healed if any breaks in integrity exist
Local Anesthetic Timing Restrictions
If lidocaine was administered intravenously during cardiac arrest management (as it may be considered for VF/pVT unresponsive to CPR, defibrillation, and vasopressor therapy 2), topical lidocaine patches must be removed or not applied until 4 hours after IV lidocaine has been discontinued 3. This prevents cumulative local anesthetic toxicity from multiple routes of administration.
Proper Application Guidelines
Dosing and Duration
When skin integrity permits and timing restrictions are met 1:
- Maximum of 3 patches to cover the most painful area
- Apply only once for up to 12 hours within a 24-hour period
- Patches may be cut to smaller sizes if needed
- Remove immediately if irritation or burning occurs
Contraindications
Absolute contraindications 1:
- Known sensitivity to amide-type local anesthetics
- Non-intact skin (critical in post-CPR patients)
- Advanced liver failure (decreased lidocaine clearance) 4
Relative contraindications requiring careful consideration 3:
- Cardiac disease (particularly relevant post-cardiac arrest)
- Electrolyte disorders
- Seizure disorders
- Renal or hepatic impairment
Clinical Context and Pitfalls
Common Mistake: Assuming Topical = Safe
The 2021 international consensus on IV lidocaine safety explicitly warns that topical 5% lidocaine patches should be removed before starting IV lidocaine infusions 3. This bidirectional caution applies equally in reverse—systemic lidocaine from resuscitation must clear before topical application.
Systemic Absorption Considerations
While pharmacokinetic studies show minimal systemic absorption with standard dosing (mean maximum plasma concentrations of 130-225 ng/mL, well below toxic levels) 5, 6, post-CPR patients may have:
- Altered perfusion affecting drug clearance
- Hepatic dysfunction from hypoxic injury
- Cardiac dysfunction affecting distribution
Limited Evidence for Chest Wall Pain
The evidence base for lidocaine patches focuses primarily on neuropathic pain (postherpetic neuralgia) 4, 7, 8 and has shown no benefit for post-sternotomy or post-thoracotomy pain in cardiac surgery patients 9. The patches did not reduce acute pain scores or opioid requirements in this population, suggesting limited utility for mechanical chest wall trauma.
Monitoring Requirements
If patches are applied after appropriate waiting period and skin assessment:
- Monitor for signs of local anesthetic toxicity (perioral tingling, tinnitus, light-headedness, restlessness) 3
- Assess application site for skin reactions (most common adverse event) 5
- Ensure lipid emulsion 20% is readily available 3
The risk-benefit ratio for Lidoderm patches in post-CPR chest pain is unfavorable given the lack of efficacy data for mechanical trauma, high likelihood of skin compromise, and potential for cumulative local anesthetic toxicity in a vulnerable population.